Company Overview and News
New Zealand shares edged higher as Tourism Holdings snapped a seven-day slide on a broker upgrade. Spark New Zealand was among several companies shedding rights to dividends.
CEN BGR FBU AIR FCREY SPKKY NZTCY SPK NZTCF FRCEF ANZFY COENY AIZ COENF GNE FBU THL ANZLY CEN ANZFF GNE MEZ GEL
New Zealand power generators pocketed an extra $5.4 billion on profits from 2010 to 2016 over and above what they would have if the wholesale electricity market was truly competitive, according to a report by a University of Auckland economist.
GNE GNE MEZ GEL
New Zealand shares rose, joining a regional rally on optimism over US-China trade relations. Fonterra Cooperative Group's first annual loss dominated local headlines.
CEN AIR FCREY NZTCF ACKDF ANZFY AUKNY AIZ KMD COENF GNE CEN KMD GEL SML KTHDY AIA FBU SPKKY NZTCY SPK FRCEF COENY AIA FBU ANZLY ANZFF GNE MEZ
Master limited partnerships (or MLPs) differ from regular stocks in that interests in them are referred to as units and unitholders (not shareholders) are partners in the business. Importantly, these hybrid entities bring together the tax benefits of a limited partnership with the liquidity of publicly traded securities. The assets that these partnerships own typically are oil and natural gas pipelines and storage facilities.
GNE CAPL GNE TRGP GEL
Stocks were indicated lower on Tuesday after the three-day weekend, but the major market equity indexes may have recently hit all-time highs after a strong earnings season. Investors have seen less upside from the “buy the dips” trends that had worked for several years. Those same investors also are trying to decide how they want their investments positioned for the rest of 2018.
BBVA FB CTSH DLTR ANET EVR ES T AAPL ADI CSCO TRI MS GEL
Midstream had a rough week, the worst since late March and 4th worst so far this year. Oil prices rallied for a second straight week, NGL prices were sharply higher, the broad stock market was higher again, but midstream and MLPs lagged badly.
NGL CCR TGE ENB CEQP GNE EQM KMI TRP WMB AMGP OKE ED KMR CVB GEL NEE TRP VLP RGCO ENB ETP GNE TRGP PBA KMRFZ
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Genesis Energy, L.P. (GEL - Free Report) recently announced that it has agreed to divest its Powder River Basin Midstream properties for around $300 million in net cash proceeds, which will be used to pay down its credit revolver’s outstanding balance. Genesis is selling the assets to a subsidiary of Dallas-based Silver Creek Midstream, LLC, which is exercising its option to buy the properties.
HLX GNE MDR GNE GEL MCDFF
TransRe, a wholly owned subsidiary of Alleghany Corporation (Y - Free Report) , announced that it has purchased exclusive renewal rights of Maiden Holdings, Ltd.’s (MHLD - Free Report) U.S. treaty reinsurance underwriting business. Also, the U.S. treaty team of Maiden Re will join TransRe. Subsequently, TransRe will offer renewal quotations for this operation, which focuses on regional property and casualty, accident and health plus personal auto insurers.
GNE MHLA MHLD PGR GNE NAVG Y GEL
Shares of Dean Foods Company (DF - Free Report) reached a 52-week low of $7.42 before closing the session a tad higher at $7.57 on Aug 29. The company has long been battling against hurdles related to input cost inflation, soft volumes in U.S. fluid milk and increased retailer investments in the private label space, which is weighing on its performance. In fact, such concerns affected the company’s second-quarter 2018 results and also compelled management to slash its 2018 earnings view.
GNE MED GNE PF GEL CHEF
By John Vandermosten, CFA ProMIS Neurosciences Inc. (TSE:PMN.TO) (OTC:ARFXF) had an encouraging year to date in 2018 over a backdrop of poor results from competitors. In January, the company found that PMN310 did not bind to amyloid beta (Aβ) plaque, thus avoiding the dose limiting ARIA-E that has plagued other less selective Aβ biologics. In March, research in an animal model found that PMN310 was able to cross the blood brain barrier at an equivalent concentration as aducanumab.
GNE GNE ARFXF GEL
Campbell Soup Company (CPB - Free Report) posted dismal earnings in fourth-quarter fiscal 2018, while sales grew owing to contributions from buyouts. However, on an organic basis, sales remained soft due to weakness in Americas Simple Meals and Beverages unit. Also, in a separate press release, the company announced various actions to improve its business as part of its strategic portfolio review. The company plans to divest non-key businesses including Campbell International and Campbell Fresh, which generated net sales of nearly $2.
GNE MED GNE PF GEL
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to GEL / Genesis Energy, L.P. on message board site Silicon Investor.
as of ET